TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Efficacy of ibudilast and TMZ combination treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of all-cause death and heart failure hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Physical component score (PCS) of the SF-36 Health Related Quality of Life (HRQoL) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post void residual volume of neobladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Oxygen uptake during incremental test to exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation during incremental test to exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Presence and Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects experiencing Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Minimum Alveolar Concentration below BIS 50 in Sevoflurane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perianal Crohn's disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Shift in functional recovery defined by the modified Rankin Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum CK value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum myoglobin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sum of 4 skinfold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected Arm Muscle Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Expression of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Section of the Unified Parkinson's Disease Rating Scale (UPDRS-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Foot ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 3-back performance on the N-back task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: total motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: embryo development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of exhaled NO (eNO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Negative PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Insulin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-Peptide Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leukemic cell turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lower extremity injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (CR) and near complete response rate (nCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tolerability of N-Acetylcysteine as assessed by drug-related symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of N-Acetylcysteine as assessed by time at which medication is taken
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Tolerability of N-Acetylcysteine as assessed by number of times medication is taken per day
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Smartphone Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of subjects discontinuing insulin use with no increase in Hemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects discontinuing insulin use with Hemoglobin A1c <7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine concentrations of leuprorelin acetate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Losing Fewer Than 15 ETDRS Letters of Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Severity Score (TSS) of Target Lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Increase in minute submaximal exercise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freeze success of the KODEX-EPD Occlusion Viewer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Posture Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural Control Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vulvar elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of Root length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time at the operating ward
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain intensity during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial insulin area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Whole body nitric oxide synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients treated according to guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: brain activation in regions of interest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pattern of refractoriness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maximum mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multidimensional Pain Inventory Interference Subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse events (AEs) and serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Limb survival proportion
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Overall Dry Skin Score (ODS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With other Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of weekly app assessments completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of Banff 2A or Higher Acute Cell-mediated Rejection and/or Acute Antibody Mediated Rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Study Defined Grade 3 or Higher Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical performance of PIK3CA kit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: T 1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of reported cases of suspected partner abuse
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: thickness change in TrA muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in Serum Albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in Serum CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Serum Prealbumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Site costs of administering IV iron
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Study Participants Who Safely Tolerated Somatokine
Endpoint domain: Adverse events/effects
Primary endpoint: Pain on ambulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient Health Questionnaire-9 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of spectacle wear
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Uncorrected Monocular Distance Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from Baseline in 24-h UFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes from Baseline in Late Night Salivary Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes from Baseline in AEs/SAEs/AESI as assessed by CTCAE V4.03
Endpoint domain: Adverse events/effects
Primary endpoint: Surgical Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rate of re-intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of post-operative delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sweat chloride measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sweat bromide measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood count changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: T lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total drusen area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 seroconversion rate
Endpoint domain: Mortality/survival
Primary endpoint: Clinically significant grade 2 laboratory findings
Endpoint domain: Adverse events/effects
Primary endpoint: Effective improvement of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of total volume and compartmental
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Level of serum vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Plasma PPi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cure rate post treatment
Endpoint domain: Mortality/survival
Primary endpoint: Incremental area under insulin concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: DNA incorporation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year local recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline mean movement velocity of affected arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline movement smoothness of affected arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline range of motion of affected arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment success on the Physician's Global Assessment (PGA) of disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical success on the Physician's Global Assessment (PASI) of disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional experiences related to eating disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cognitive experiences related to eating disorders
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relational experiences related to eating disorders
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Geometric changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychoeducational Profile, Third Edition (PEP-3)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Childhood Autism Rating Scale (CARS-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale (mRS) at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Safety of study drug
Endpoint domain: Adverse events/effects
Primary endpoint: Daily Life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Alcohol Craving Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in number of subjects reporting treatment related AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cognitive insight
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in clinical insight
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical signs and symptoms assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in KOOS over baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average luteinizing hormone (LH) interpulse interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total number of LH pulses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Global cardiovascular disease risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maternal Emotion Dysregulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of pulmonary arterial pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Global Flushing Severity Score (GFSS) ≥4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the difficulties in emotion regulation scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Abnormal histological finding at breast biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Caregiver Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Subjects With a Greater Than or Equal to 50% Decrease in Sperm Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Lung atelectasis score after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity to change of US pathology in joints and entheses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distance between two needle insertion points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in urinary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in sexual function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Gastrointestinal function and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Aortic pulse wave velocity (PWV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specific health needs of the transpopulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk factors for COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Antiretroviral Therapy (ART) Adherence Levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PFS improvement
Endpoint domain: Mortality/survival
Primary endpoint: Human Milk Macro Nutrients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of ceftobiprole in the blood and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to recurrence of mood event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NK cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Size of the HIV reservoir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of refeeding syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Total-body-less head bone mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total-body-less head bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in incidence of loose/watery stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mortality rate reduction
Endpoint domain: Mortality/survival
Primary endpoint: organ damage reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of wrinkles grade of the area around the eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Variation of Wrinkle Severity Rating Scale (WSRS) grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Variation of Facial Volume Loss Scale (FVLS) grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pacing voltage threshold at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pacing impedance at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensed amplitude at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lead complication-free rate up to 3 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Visual capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality-of-life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cumulative percentage of bradycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative percentage of desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Overall aerobic work performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Experienced Cycle 1 Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Signal intensity by Diffusion MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Banff score (histopathologic findings)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in diffusion parameters of the white matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in the Monthly Average Number of Migraine Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration to align the lower labial segment (33-43)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of self-administered assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical utility of assessment tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: cell proliferation rates in tumour tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Emergency Department Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Upper Extremity-Fugl Meyer Assessment (UE-FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaginal prolapse symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of frequency and intensity of vasomotor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic-mucosal Associated Microbial Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic-mucosal Associated Metabolomic Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Feeding Attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of antibiotic non-adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prophylactic treatment compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes